Affiliate of CORT (NASDAQ: CORT) files Form 144 to offer 5,000 shares
An affiliate of Corcept Therapeutics (NASDAQ: CORT) has filed a Form 144 indicating an intent to sell 5,000 shares of common stock, valued at $291,100.00. Fidelity Brokerage Services LLC is listed as the broker for this proposed transaction, which was filed on May 20, 2026. The filing provides details on the acquisition history of these securities by the seller, including various stock awards and purchases.
Corcept Therapeutics Inc. (CORT) Stock Analysis: Exploring a 40.15% Potential Upside for Biotech Investors
Corcept Therapeutics Inc. (CORT) is gaining investor attention due to its focus on developing treatments for severe endocrinologic, oncologic, metabolic, and neurologic disorders, with its stock currently trading at $56.37. Despite a recent modest decline, analysts foresee a 40.15% potential upside, with an average target price of $79.00. The company's positive analyst ratings, robust pipeline of selective cortisol modulators, and solid financial foundation suggest an intriguing opportunity for growth-oriented investors in the biotech sector.
Corcept (CORT) chief business officer reports 7,300-share gift of common stock
Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, reported gifting a total of 7,300 shares of common stock on May 13, 2026. These gifts included 5,300 shares from his direct holdings and two separate 1,000-share gifts from custodial accounts for a child. Following these transactions, Robb's direct holdings stand at 24,487 shares, with additional indirect holdings in custodial accounts and a revocable trust, along with unvested restricted stock awards.
A Look At Corcept Therapeutics (CORT) Valuation After Higher 2026 Guidance And New ALS Trial Data
Corcept Therapeutics (CORT) reported a Q1 net loss but raised its 2026 revenue guidance, projecting between US$950 million and US$1.05 billion, partly due to FDA approval of Lifyorli and strong prescription trends. The company also released promising two-year survival data from its Phase 2 DAZALS ALS study. Despite a recent share price decline, its 30-day and 3-year returns remain positive, leading to discussions about whether the stock is undervalued given the updated guidance and pipeline data, or if its rich P/E multiple suggests overvaluation.
Corcept’s ALS Survival Signal Reframes Cortisol Modulation And Growth Outlook
Corcept Therapeutics reported promising long-term survival data from its DAZALS Phase 2 trial for dazucorilant in ALS, showing an 87% reduction in death risk for patients on a 300 mg daily dose, despite not meeting the primary functional endpoint. This new finding enhances Corcept's neurology pipeline, diversifying its focus beyond hypercortisolism and ovarian cancer, amid recent financial fluctuations including a quarterly net loss but raised 2026 revenue guidance. Investors are now watching how regulators react to the survival data and how the company manages R&D costs alongside its expanding drug portfolio.
Corcept (CORT) CDO sells 20K shares under 10b5-1 plan
Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and sold 20,000 shares of common stock on May 5, 2026, under a pre-arranged Rule 10b5-1 trading plan. He acquired the shares at $21.65 each and sold them at a weighted average price of $51.83. Following these transactions, Guyer holds 2,231 common shares and 170,000 fully exercisable stock options.
Corcept Therapeutics Incorporated - Common Stock (NQ: CORT)
This article compiles a series of press releases and investor alerts concerning a securities class action lawsuit against Corcept Therapeutics, Inc. (NASDAQ: CORT). Various law firms, including Kaplan Fox, Kirby McInerney, Pomerantz, Rosen, Schall, Lewis Kahn, Bernstein Liebhard, Bragar Eagel & Squire, and Grabar Law Office, are encouraging investors to contact them regarding potential losses and upcoming deadlines, largely around April 21, 2026. The lawsuits stem from alleged securities fraud, including issues related to FDA approval and a significant stock decline.
Vanguard Group Inc. Has $330.42 Million Holdings in Corcept Therapeutics Incorporated $CORT
Vanguard Group Inc. reduced its stake in Corcept Therapeutics (CORT) by 0.4% in the fourth quarter, now holding 9,494,822 shares valued at $330.42 million. Despite Corcept missing Q1 consensus estimates for EPS and revenue, several analysts have upgraded price targets, leading to a "Moderate Buy" consensus and a $74.67 target price. The article also highlights recent insider selling by the CEO and another insider, totaling over $2.3 million in transactions.
Corcept (NASDAQ: CORT) CEO sells 40K shares under 10b5-1 plan
Corcept Therapeutics CEO Joseph K. Belanoff sold 40,000 shares of common stock on May 1, 2026, for approximately $2 million, through a pre-arranged Rule 10b5-1 trading plan. The shares were sold indirectly via a revocable living trust at a weighted average price of $50.0965 per share. Following this transaction, the trust retains 2,878,326 shares of Corcept Therapeutics.
How many employees work at Corcept Therapeutics?
Corcept Therapeutics, Inc. had 684 employees as of December 2025, according to Revelio Labs data, representing a 40.5% year-over-year growth rate. The company focuses on discovering drugs that modulate cortisol effects for various metabolic, oncological, and psychiatric diseases. The article also provides historical employee headcount data and active job postings from 2023 to 2025.
Corcept Therapeutics (NASDAQ: CORT) affiliate plans sale of 20,000 shares via Stifel
Corcept Therapeutics Inc. has filed a Form 144 indicating an intended sale of 20,000 shares of common stock through Stifel Nicolaus & Company Inc. on May 5, 2026. This transaction is a stock option exercise settled for cash. The filing also notes three prior dispositions by William Guyer, totaling 40,000 shares, that occurred between March and April 2026.
Corcept Therapeutics (NasdaqCM:CORT) Stock Forecast & Analyst Predictions
Corcept Therapeutics (CORT) is projected to see significant growth in earnings and revenue, with analysts forecasting 48.7% and 22.1% annual increases, respectively. Despite a forecasted low return on equity of 5.9% in three years, recent positive updates include FDA approval for Lifyorli and advancements in ALS trials, contributing to increased price targets from some analysts. However, the company faces challenges such as patent rulings allowing generic competition and some analysts reducing price targets due to revised revenue growth expectations.
Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. has reiterated its "Buy" rating on Corcept Therapeutics (CORT). This indicates a continued positive outlook from the firm regarding the company's stock performance.
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $110
CCORF has reiterated its Buy rating on Corcept Therapeutics (CORT.US) and maintained its target price of $110. This indicates a continued positive outlook from the firm regarding Corcept Therapeutics' stock performance.
Corcept Therapeutics Is Maintained at Overweight by Piper Sandler
Piper Sandler has maintained its "Overweight" rating on Corcept Therapeutics. The article title provides this key information, indicating a positive outlook from the analyst firm for the company.
Corcept Therapeutics (CORT) reports Q1 loss, misses revenue estimates
This article reports that Corcept Therapeutics (CORT) announced a Q1 loss and missed revenue estimates. No specific financial figures or details are available in the provided content.
Is Corcept Therapeutics (CORT) Pricing Make Sense After Recent Volatility In The Share Price
Corcept Therapeutics (CORT) stock has experienced significant volatility, with recent gains but a 29.3% decline over the past year. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 84.4%, with an estimated intrinsic value of $329.41 per share compared to its current price of approximately $51.42. However, its high P/E ratio of 120.36x, significantly above industry and peer averages, indicates it might be overvalued based on earnings multiples.
Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth
Corcept Therapeutics reported first-quarter 2026 revenue of $164.9 million, an increase from the previous year, despite posting a net loss due to higher operating expenses for the launch of Lifyorli and growth investments. The company expects to return to profitability in Q2 2026 and has raised its full-year revenue guidance to $950–$1,050 million, driven by the FDA approval of Lifyorli for ovarian cancer and its inclusion in NCCN Guidelines. Corcept is also advancing other drug candidates to diversify its revenue beyond its existing Cushing’s syndrome treatments.
Corcept Therapeutics (CORT) insider notifies sale of 40,000 shares via Stifel
A Corcept Therapeutics (CORT) insider has filed a Rule 144 notice for the proposed sale of 40,000 shares of common stock through Stifel Nicolaus & Company Inc., valued at approximately $1,860,800. The filing also disclosed a prior sale of 26,198 shares on March 25, 2026, which generated proceeds of $1,311,825. This proposed sale originates from a stock option exercise on July 6, 2022.
FDA cancer approval lifts Corcept (NASDAQ: CORT) 2026 outlook and spend
Corcept Therapeutics reported mixed Q1 2026 results with increased revenue but a net loss due to higher operating expenses for the Lifyorli launch and Cushing’s growth initiatives. The company's 2026 revenue guidance was raised to $950–$1,050 million following FDA approval of Lifyorli for platinum-resistant ovarian cancer and promising ALS survival data for dazucorilant, with a return to profitability expected in Q2 2026. This reflects a strategic shift towards R&D and launch spending for long-term growth.
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
Corcept Therapeutics reported Q1 2026 revenues of $164.9 million, a slight increase from Q1 2025, but a net loss of $31.8 million due to increased spending on clinical trials and the launch of Lifyorli. The company raised its 2026 revenue guidance to $950 – $1,050 million and expects to return to profitability in Q2 2026, driven by the recent FDA approval of Lifyorli for platinum-resistant ovarian cancer and growth in its Cushing's syndrome business. Corcept also provided updates on its diverse clinical development pipeline, including treatments for Cushing's syndrome, various cancers, MASH, and ALS.
Earnings call transcript: Corcept Therapeutics Q1 2026 raises guidance amid Lifyorli launch
Corcept Therapeutics reported strong Q1 2026 results, with revenue up 4.9% year-over-year to $164.9 million, driven by their endocrinology and oncology segments. Despite a net loss due to strategic investments for growth, the company significantly raised its full-year guidance to $950 million - $1.05 billion, projecting 21-34% growth. This optimism is fueled by the successful launch and rapid market adoption of Lifyorli for ovarian cancer and continued strength in their Cushing's syndrome business, alongside promising pipeline developments in MASH and ALS.
(CORT) Corcept Therapeutics Expects 2026 Revenue Range $950M-$1.05B, vs. FactSet Est of $899.5M
Corcept Therapeutics (CORT) projects its 2026 revenue to be between $950 million and $1.05 billion, surpassing FactSet's estimated $899.5 million. The company recently reported its Q1 results, swinging to a loss despite increased revenue, and subsequently raised its full-year guidance. This announcement follows several recent developments, including FDA approval for its drug Lifyorli for platinum-resistant ovarian cancer and positive data from clinical trials.
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
Corcept Therapeutics reported first-quarter 2026 revenue of $164.9 million, revising its full-year guidance upwards to $950-$1,050 million, largely due to the FDA's recent approval of Lifyorli (relacorilant) for platinum-resistant ovarian cancer. While the company incurred a net loss of $31.8 million for the quarter, it anticipates a return to profitability in Q2 2026, driven by Lifyorli's strong initial uptake and increased demand for its Cushing's syndrome medications. Corcept also provided updates on its diverse clinical pipeline, including ongoing trials for Cushing's syndrome, various cancers, MASH, and ALS, highlighting promising results and future development plans.
Corcept: Q1 Earnings Snapshot
Corcept Therapeutics Inc. (CORT) reported a first-quarter loss of $31.2 million, or 30 cents per share, meeting analyst expectations. However, the drug developer's revenue of $164.9 million fell short of Street forecasts of $172.4 million. Corcept anticipates full-year revenue to be between $950 million and $1.05 billion.
Corcept (CORT) director-linked trust gifts 2,000 company shares
Corcept Therapeutics director James N. Wilson, through an associated trust, reported a bona fide gift of 2,000 shares of Corcept common stock on April 22, 2026. This transaction is categorized as a non-market transfer, and the James N. Wilson and Pamela D. Wilson Trust still holds over 1 million shares after the gift. The regulatory filing details other indirect holdings and notes that Wilson disclaims beneficial ownership of certain shares except for his pecuniary interest.
Boston Trust Walden Corp Sells 34,635 Shares of Corcept Therapeutics Incorporated $CORT
Boston Trust Walden Corp decreased its stake in Corcept Therapeutics (NASDAQ:CORT) by 6.2% in the fourth quarter, selling 34,635 shares, but still holds over half a million shares valued at $18.36 million. Despite high institutional ownership and significant increases from several large investors, insiders have recently sold shares, and analysts have a "Moderate Buy" consensus with an average target price of $77.67. The company recently missed Q4 earnings and revenue estimates.
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics Incorporated announced it will report its first quarter financial results and provide a corporate update on April 30, 2026. The company will host a conference call on the same day at 5:00 p.m. Eastern Time. Interested participants must register in advance for the call, and a listen-only webcast will also be available.
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics (NASDAQ: CORT) announced it will release its first-quarter financial results and provide a corporate update on April 30, 2026. The company will also host a conference call at 5:00 p.m. Eastern Time on that day. Participants must register in advance for the call, with a listen-only webcast also available.
Corcept Therapeutics (CORT.US)$ all in
The article is a very brief post in the moomoo Community, stating "Corcept Therapeutics (CORT.US) all in." It appears to be a personal investment statement rather than an analytical piece. The content provided is primarily navigation and disclaimers from the moomoo platform.
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
Corcept Therapeutics will present new data from its pivotal Phase 3 ROSELLA trial of Lifyorli plus nab-paclitaxel in platinum-resistant ovarian cancer at the 2026 ASCO Annual Meeting. Lifyorli, the first FDA-approved selective glucocorticoid receptor antagonist for this condition, was sanctioned in March 2026 and is included in NCCN Guidelines as a preferred regimen. The data will focus on overall survival subgroup analyses based on prior taxane use, highlighting the drug's role in a challenging cancer with limited treatment options.
INGALLS & SNYDER (NASDAQ: CORT) reports 7.26M shares (6.8%)
INGALLS & SNYDER, LLC has filed an amended Schedule 13G/A, reporting beneficial ownership of 7,263,466 shares of CORCEPT THERAPEUTICS INC (NASDAQ: CORT) common stock, which represents 6.8% of the class as of December 31, 2025. The filing indicates shared dispositive power over all these shares and no sole voting power, signifying a passive investment position. This amendment, signed on April 21, 2026, provides key figures and regulatory insights into this significant stake.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives Average Recommendation of "Moderate Buy" from Brokerages
Corcept Therapeutics (NASDAQ:CORT) has received an average "Moderate Buy" recommendation from brokerages, with an average 12-month price target of $77.67. This comes amidst mixed signals, including recent missed quarterly earnings expectations and multiple securities class-action lawsuits, contrasting with an insider purchase of 100,000 shares and high institutional ownership. Analyst ratings vary from "sell" to "strong buy," reflecting the conflicted outlook for the company.
Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit
The Rosen Law Firm is reminding purchasers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock who suffered losses exceeding $100,000 during the Class Period (October 31, 2024, and December 30, 2025) of the April 21, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Corcept misrepresented the adequacy of clinical trials for relacorilant, leading investors to believe FDA approval was imminent when the FDA had repeatedly raised concerns. Investors can join the class action to seek compensation.
Corcept to present ovarian cancer trial data at ASCO meeting
Corcept Therapeutics will present new data from its Phase 3 ROSELLA trial at the American Society of Clinical Oncology Annual Meeting on May 29, 2026, focusing on overall survival subgroup analyses in platinum-resistant ovarian cancer patients. The company's drug, Lifyorli (relacorilant plus nab-paclitaxel), recently received FDA approval and is the first FDA-approved selective glucocorticoid receptor antagonist for this condition. Corcept, valued at $4.76 billion, anticipates 21% revenue growth for fiscal 2026.
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
Corcept Therapeutics will present new data from its pivotal Phase 3 ROSELLA trial of Lifyorli™ (relacorilant) plus nab-paclitaxel in platinum-resistant ovarian cancer at the 2026 ASCO Annual Meeting. Lifyorli, the first FDA-approved selective glucocorticoid receptor antagonist, was approved in March 2026 for this patient population. The presentation will include overall survival subgroup analyses.
CORT DEADLINE ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Today's Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit
Hagens Berman has issued a deadline alert for investors in Corcept Therapeutics (CORT) regarding a securities fraud class action lawsuit. Investors who suffered significant losses between October 31, 2024, and December 30, 2025, are urged to submit their losses by the April 21, 2026, lead plaintiff deadline. The lawsuit alleges Corcept concealed FDA warnings about its drug candidate, relacorilant, leading to a significant stock price drop after a Complete Response Letter from the FDA.
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors
The Portnoy Law Firm has announced a class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of investors who purchased securities between October 31, 2024, and December 31, 2025. The lawsuit alleges that Corcept misrepresented the strength of evidence supporting its relacorilant New Drug Application, which was ultimately rejected by the FDA due to insufficient clinical evidence of efficacy. Corcept investors have until April 21, 2026, to file a lead plaintiff motion.
CORT FINAL DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action -
The Rosen Law Firm is reminding investors who purchased Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, of the April 21, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that Corcept misrepresented the adequacy of clinical trials for relacorilant, concealing FDA concerns that ultimately hindered its approval. Investors with losses exceeding $100K are encouraged to secure counsel before the deadline.
Levi & Korsinsky Notifies Shareholders of Corcept
Levi & Korsinsky, LLP has notified investors of Corcept Therapeutics Incorporated (NASDAQ: CORT) about a class action securities lawsuit. The lawsuit alleges securities fraud between October 31, 2024, and December 30, 2025, claiming that positive statements regarding FDA interactions and the approval of the relacorilant NDA were materially false or misleading. Investors who suffered losses have until April 21, 2026, to request to be appointed as lead plaintiff.
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz announced that investors who suffered losses in Corcept Therapeutics Incorporated (CORT) have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that Corcept and its defendants failed to disclose critical information about FDA concerns regarding relacorilant's effectiveness in treating hypertension and issues with the GRACE trial study, making their public statements misleading. Investors have until April 21, 2026, to participate as a lead plaintiff in the ongoing lawsuit.
CORT DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Corcept Therapeutics Incorporated Investors to Join the Class Action Lawsuit Today
Bronstein, Gewirtz & Grossman, LLC reminds investors of the class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ:CORT). The lawsuit alleges that Corcept and its officers made materially false and misleading statements regarding the strength of clinical trials for relacorilant and its regulatory approval prospects. Investors who purchased Corcept securities between October 31, 2024, and December 30, 2025, are encouraged to join the lawsuit, with a lead plaintiff deadline of April 21, 2026.
CORCEPT DEADLINE TOMORROW: Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Corcept Therapeutics Incorporated, urging investors who bought common stock between October 31, 2024, and December 30, 2025, to contact the firm before the deadline of April 21, 2026. The lawsuit alleges that Corcept misrepresented the approval prospects of its new drug candidate, relacorilant, leading to a significant stock drop after the FDA issued a Complete Response Letter. Investors are encouraged to apply as lead plaintiff to discuss their legal options.
CORT SHAREHOLDER ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Hagens Berman has issued a shareholder alert for Corcept Therapeutics (NASDAQ: CORT) investors, announcing a securities class action lawsuit. This follows the FDA's rejection of Corcept's lead drug candidate, relacorilant, and a significant stock price drop. Investors who suffered losses between October 31, 2024, and December 30, 2025, are encouraged to contact the firm before the April 21, 2026, lead plaintiff deadline.
CORT SHAREHOLDER ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Hagens Berman has announced a securities class action lawsuit against Corcept Therapeutics (CORT) following the FDA's rejection of its lead drug candidate, relacorilant, and a subsequent 50% stock price drop. Investors who suffered significant losses between October 31, 2024, and December 30, 2025, are encouraged to contact the firm before the April 21, 2026, lead plaintiff deadline. The lawsuit alleges that Corcept concealed repeated FDA warnings about insufficient evidence of relacorilant's effectiveness while touting its potential approval.
CORT FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action - CORT
The Rosen Law Firm is reminding investors of Corcept Therapeutics Incorporated (NASDAQ: CORT) who suffered losses exceeding $100,000 to secure legal counsel by the April 21, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Corcept made misleading statements regarding the New Drug Application (NDA) for relacorilant, specifically concerning the adequacy of its clinical evidence and its likelihood of FDA approval. Investors who purchased CORT stock between October 31, 2024, and December 30, 2025, may be entitled to compensation.
Corcept Therapeutics Shareholder Class Action Reminder
Hagens Berman is reminding Corcept Therapeutics (CORT) investors that April 21, 2026, is the deadline to apply as lead plaintiff in a class action lawsuit. The lawsuit alleges that Corcept failed to disclose critical information to the FDA regarding its drug relacorilant, leading to a significant stock price drop following a Complete Response Letter. Investors who suffered losses are urged to submit their claims promptly.
CORT SHAREHOLDER ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Hagens Berman has issued a shareholder alert for Corcept Therapeutics (CORT) investors, informing them of a securities class action lawsuit. The lawsuit alleges that Corcept's management concealed repeated FDA warnings about insufficient data for its lead drug candidate, relacorilant, despite publicly touting its pipeline readiness. This class action follows a significant stock price drop after the FDA issued a Complete Response Letter (CRL) due to an "insufficient" evidentiary record, causing Corcept's market capitalization to plummet by nearly $2.5 billion in one day.
CORT SHAREHOLDER ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Hagens Berman has issued a shareholder alert for Corcept Therapeutics (CORT) investors, announcing a securities class action lawsuit. The lawsuit alleges that Corcept's management concealed repeated FDA warnings about insufficient data for their lead drug candidate, relacorilant, while falsely touting its pipeline readiness. This comes after the FDA issued a Complete Response Letter, causing Corcept's stock to plummet by 50% in a single day.
CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Corcept Therapeutics ...
The Gross Law Firm has issued a shareholder alert for Corcept Therapeutics Incorporated (NASDAQ: CORT), urging investors who purchased shares during the class period of October 30, 2020, to December 23, 2023, to contact the firm. The alert concerns allegations that Corcept made false statements or concealed information regarding the adequacy of its relacorilant program assessment, especially concerning FDA concerns about its GRACE study design and potential approval issues. Shareholders have until April 21, 2026, to seek lead plaintiff appointment in the class action lawsuit.
